How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%Zacks Investment Research • 10/19/26
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026GlobeNewsWire • 10/06/26
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000The Motley Fool • 09/11/26
Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/10/26
Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The WatchlistSeeking Alpha • 08/26/26
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsGlobeNewsWire • 08/11/26
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 07/21/26
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?The Motley Fool • 06/29/26
Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?The Motley Fool • 06/05/26
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue EstimatesZacks Investment Research • 05/12/26
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsGlobeNewsWire • 05/12/26
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.The Motley Fool • 04/04/26
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)Zacks Investment Research • 03/27/26
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewsWire • 03/26/26
Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%The Motley Fool • 03/25/26